HTML Microdata document

This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/bindingdb/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/kegg-compound/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
foaf	http://xmlns.com/foaf/0.1/
n5	http://linked.opendata.cz/resource/drugbank/company/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/kegg-drug/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/iuphar/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/drugbank/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/guide-to-pharmacology/
n21	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
n25	http://www.drugs.com/mtm/
n18	http://www.rxlist.com/cgi/generic/
n13	http://linked.opendata.cz/resource/drugbank/patent/
n7	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n14	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/chebi/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n11	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/wikipedia/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00604/identifier/pharmgkb/
n9	http://linked.opendata.cz/resource/atc/
n8	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00604
rdf:type: n3:Drug
n3:description: In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
n3:generalReferences: # Pearce RE, Gotschall RR, Kearns GL, Leeder JS: Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11717173
n3:group: withdrawn approved investigational
n3:halfLife: 6-12 hours
n3:indication: For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.
n3:manufacturer: n5:271B548F-363D-11E5-9242-09173F13E4C5 n5:271B5490-363D-11E5-9242-09173F13E4C5
owl:sameAs: n7:DB00604 n21:DB00604
dcterms:title: Cisapride
adms:identifier: n11:Cisapride n14:3720 n15:DB00604 n16:50005836 n19:240 n20:C06910 n22:240 n23:D00274 n24:PA449011
n3:mechanismOfAction: Cisapride acts through the stimulation of the serotonin 5-HT<sub>4</sub> receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.
n3:packager: n5:271B5489-363D-11E5-9242-09173F13E4C5 n5:271B548D-363D-11E5-9242-09173F13E4C5 n5:271B548E-363D-11E5-9242-09173F13E4C5 n5:271B548B-363D-11E5-9242-09173F13E4C5 n5:271B548C-363D-11E5-9242-09173F13E4C5 n5:271B548A-363D-11E5-9242-09173F13E4C5
n3:patent: n13:5648093
n3:synonym: cis-4-amino-5-chloro-N-{1-[3-(P-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl}-O-anisamide Cisaprida 4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-3-methoxy-piperidin-4-yl}-2-methoxy-benzamide 4-amino-5-chloro-N-(1-(3-(4-Fluorophenoxy)propyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide Cisaprid Cisapride (+-)-Cisapride cis-4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl}-2-methoxybenzamide cis-4-amino-5-chloro-N-(1-(3-(P-Fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-O-anisamide Cisapridum
n3:foodInteraction: Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can significantly increase serum levels of this product. Increases absorption, take 30 minutes before a meal.
n3:proteinBinding: 97.5%
n3:salt
n3:synthesisReference: Alfons Gaston Maria De Knaep, Luc Jozef Raphael Moens, Max Rey, "Synthesis of cisapride." U.S. Patent US6218542, issued January, 1988.
foaf:page: n18:cisap.htm n25:cisapride.html
n3:IUPAC-Name: n4:271B5495-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B549B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B549A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B5497-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B5498-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B5499-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B54AB-363D-11E5-9242-09173F13E4C5 n4:271B5493-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B5491-363D-11E5-9242-09173F13E4C5 n4:271B54AD-363D-11E5-9242-09173F13E4C5 n4:271B5494-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B5492-363D-11E5-9242-09173F13E4C5
n8:hasATCCode: n9:A03FA02
n3:H-Bond-Acceptor-Count: n4:271B54A1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B54A2-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B549C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B549D-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B549F-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B549E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B54A0-363D-11E5-9242-09173F13E4C5
n3:absorption: Cisapride is rapidly absorbed after oral administration, with an absolute bioavailability of 35-40%.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 81098-60-4
n3:category
n3:Bioavailability: n4:271B54A7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B54A9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B54AA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B54AC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B54A6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B54A5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B54A8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B5496-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B54A3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B54A4-363D-11E5-9242-09173F13E4C5